MYGN
$11.64
Myriad Genetics
$.08
.69%
MYGN
Earnings Whisper ®
N/A
4th Quarter June 2020
Consensus:  ($0.49)
Revenue:  $113.73 Mil
Tuesday
Aug 4
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MYGN reports earnings?
Beat
Meet
Miss

Where is MYGN's stock price going from here?
Up
Flat
Down
Stock chart of MYGN
Analysts
Summary of analysts' recommendations for MYGN
Score
Grade
Pivots
Resistance
$12.36
$12.10
$11.87

$11.62

Support
$11.39
$11.13
$10.90
Tweet
Growth
Description
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.
Peers
ImmunomedicsCareDxQuidelSurModicsMeridian Bioscience